EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Other Site of Rhabdomyosarcoma

Leonie Kern, Anton Henssen, Angelika Eggert, Monika Scheer iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Leonie Kern und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Univer…. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, SEER Program. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rhabdomyosarcoma (RMS) is a rare malignant soft tissue sarcoma (STS), accounting for almost 50% of pediatric STSs. Due to its heterogeneity, RMS presents challenges in diagnosis and treatment, with prognosis varying depending on multiple factors. Tumors localized in the other site (OTH)—including the paraspinal, perianal, thoracic, abdominal, pelvic, and perineal regions—are generally classified as unfavorable. This study assesses the clinical features and prognoses of RMS in OTH locations depending on its site of origin.

Methods

An explorative analysis of RMS cases from the SEER 17 database 2000–2020 was conducted. Patients of all ages with histologically confirmed RMS as primary malignant disease classified under OTH, were included. OTH was categorized in four granular site classifications. Overall survival (OS) and disease‐specific survival (DSS) were analyzed using Kaplan–Meier estimators. Factors independently influencing survival, including a site classification model presented in this study, were identified through Cox regression analysis.

Results

Out of 4168 patients with RMS, 990 cases of RMS with the OTH site met the inclusion criteria. The median age was 16 years. The predominant histological subtypes were embryonal (33.0%) and alveolar (25.5%). Most tumors were ≥ 5 cm (median 9 cm) and located primarily in the pelvic region (41.5%). The 3‐, 5‐, and 10‐year OS rates were 45.4% ± 3.332 (95% CI), 40.7 ± 3.332, and 38.6% ± 3.332, respectively, while DSS rates were 43.3% ± 3.136 (95% CI), 38.3% ± 3.136, and 35.1% ± 3.332. In the multivariate analysis age, histological type, site in a granular categorization, stage, regional lymph node examination, and regional lymph node involvement (pathologically proven) were independently associated with survival. Through both univariate and multivariate analyses, an OTH favorable group could be established. The OTH favorable group consists of the anal region, gallbladder and biliary tract, and breast.

Conclusion

RMS in OTH shows significant differences in prognosis, putting the current categorization as unfavorable into question and making a more detailed classification necessary. Furthermore, pathological regional lymph node assessment is specifically in the OTH localization recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhabdomyosarcomaSEER ProgramHumansMaleFemaleAdolescentChildChild, PreschoolAdultYoung AdultInfantPrognosisMiddle AgedKaplan-Meier Estimate

Stichwörter der Autor:innen

adult sarcomaageage‐spanninglymph nodesother sitepediatric sarcomarhabdomyosarcomasoft tissue sarcoma

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

ORCID-Profile: Monika Scheer

Zitieren

APA

Kern, L., Henssen, A., Eggert, A., & Scheer, M. (2024). The Other Site of Rhabdomyosarcoma. Cancer Medicine. https://doi.org/10.1002/cam4.70348

Vancouver

Kern L, Henssen A, Eggert A, Scheer M. The Other Site of Rhabdomyosarcoma. Cancer Medicine. 2024. doi:10.1002/cam4.70348

BibTeX
@article{Kern2024,
  author = {Kern, Leonie and Henssen, Anton and Eggert, Angelika and Scheer, Monika},
  title = {The Other Site of Rhabdomyosarcoma},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70348}
}
Kostenlos starten →